Novel agents for the treatment of chronic lymphocytic leukemia.

  title={Novel agents for the treatment of chronic lymphocytic leukemia.},
  author={Karim E. Abou-Nassar and Jennifer Rose Brown},
  journal={Clinical advances in hematology & oncology : H&O},
  volume={8 12},
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. Currently, the most effective treatment for CLL consists of a combination of fludarabine, cyclophosphamide, and rituximab. Although this approach has encouraging results, patients with CLL eventually relapse and require additional therapies. Many of the current therapeutic regimens for CLL are myelotoxic, immunosuppressive, and associated with infectious complications. Targeted therapies can often minimize… CONTINUE READING
15 Citations
69 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 15 extracted citations


Publications referenced by this paper.
Showing 1-10 of 69 references

$e cyclin dependent kinase inhibitor SCH 727965 demonstrates promising pre-clinical and early clinical activity in chronic lymphocytic leukemia

  • JM Flynn, AJ Johnson, L Andritsos
  • Blood (ASH Annual Meeting Abstracts)
  • 2009

$e histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells

  • B Stamatopoulos, N Meuleman, C De Bruyn
  • Hematologica
  • 2009

Similar Papers

Loading similar papers…